BioSpace7h
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More
Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...
BMO maintains Novo Nordisk stock target post FDA nod
BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) shares, maintaining an Outperform rating and a $105.00 price target. This confirmation followed the U.S. Food and Drug ...
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
Leerink maintains Tectonic stock Outperform with $69 target
Leerink Partners analyst David Risinger noted the significant concern about the likelihood of success of TX45 in PH-HFpEF ...
Novo’s Ozempic Notches Approval for Kidney Disease, Widening Use
Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...